Single-agent thalidomide induces response in T-cell lymphoma

被引：13

作者：

Damaj, G ^{[1
]}

Bouabdallah, R ^{[1
]}

Vey, N ^{[1
]}

Bilger, K ^{[1
]}

Mohty, M ^{[1
]}

Gastaut, JA ^{[1
]}

机构：

[1] Inst Paoli Calmettes Canc Ctr, Marseille, France

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2005年 / 74卷 / 02期

关键词：

thalidomide; lymphoma;

D O I：

10.1111/j.1600-0609.2004.00362.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

T-cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response.

引用

页码：169 / 171

页数：3

共 24 条

[1]

Corral LG, 1999, J IMMUNOL, V163, P380

[2] Thalidomide therapy induces response in relapsed mantle cell lymphoma [J].

Damaj, G ;

Lefrère, F ;

Delarue, R ;

Varet, B ;

Furman, R ;

Hermine, O .

LEUKEMIA, 2003, 17 (09) :1914-1915

[3] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[4] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[5] Treatment of Waldenstrom's macroglobulinemia with thalidomide [J].

Dimopoulos, MA ;

Zomas, A ;

Viniou, NA ;

Grigoraki, V ;

Galani, E ;

Matsouka, C ;

Economou, O ;

Anagnostopoulos, N ;

Panayiotidis, P .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3596-3601

[6] Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies [J].

Giovanni, B ;

Michelle, E ;

Letizia, C ;

Filippo, B ;

Paolo, PP ;

Giuseppe, V ;

Monia, M ;

Gabriele, P ;

Francesca, Z ;

Ayalew, T .

LEUKEMIA & LYMPHOMA, 2002, 43 (12) :2301-2307

[7]

Gisselbrecht C, 1998, BLOOD, V92, P76

[8] Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients [J].

Haslett, PAJ ;

Klausner, JD ;

Makonkawkeyoon, S ;

Moreira, A ;

Metatratip, P ;

Boyle, B ;

Kunachiwa, W ;

Maneekarn, N ;

Vongchan, P ;

Corral, LG ;

Elbeik, T ;

Shen, Z ;

Kaplan, G .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (13) :1169-1179

[9] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[10] Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma [J].

Kaufmann, H ;

Raderer, M ;

Wöhrer, S ;

Püspök, A ;

Bankier, A ;

Zielinski, C ;

Chott, A ;

Drach, J .

BLOOD, 2004, 104 (08) :2269-2271

← 1 2 3 →